日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

双重细胞焦亡生物标志物可预测接受来那度胺和重组人红细胞生成素治疗的低危非del(5q)骨髓增生异常综合征患者的红系反应

Wang, Chen; McGraw, Kathy L; McLemore, Amy F; Komrokji, Rami; Basiorka, Ashley A; Al Ali, Najla; Lancet, Jeffrey E; Padron, Eric; Kosmider, Olivier; Fontenay, Michaela; Fenaux, Pierre; List, Alan F; Sallman, David A

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study

评估 ASC 斑点作为骨髓增生异常综合征中细胞焦亡的假定生物标志物:一项观察性队列研究

Ashley A Basiorka, Kathy L McGraw, Farnoosh Abbas-Aghababazadeh, Amy F McLemore, Nicole D Vincelette, Grace A Ward, Erika A Eksioglu, David A Sallman, Najla Al Ali, Eric Padron, Javier Pinilla-Ibarz, Rami Komrokji, Erico Masala, Valeria Santini, Olivier Kosmider, Michaela Fontenay, Pierre Fenaux, Lu

Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS

与年龄相关的炎症性骨髓微环境诱导无效红细胞生成,类似 del(5q) MDS

Y Mei, B Zhao, A A Basiorka, J Yang, L Cao, J Zhang, A List, P Ji

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858

通过使用 Fc 工程化 CD33 抗体 BI 836858 靶向 MDSC 来改善低风险 MDS 造血功能的新型治疗方法

E A Eksioglu, X Chen, K-H Heider, B Rueter, K L McGraw, A A Basiorka, M Wei, A Burnette, P Cheng, J Lancet, R Komrokji, J Djeu, A List, S Wei

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

促炎蛋白 S100A9 和肿瘤坏死因子-α 抑制骨髓增生异常综合征中的促红细胞生成素生成

Thomas Cluzeau, Kathy L McGraw, Brittany Irvine, Erico Masala, Lionel Ades, Ashley A Basiorka, Jaroslaw Maciejewski, Patrick Auberger, Sheng Wei, Pierre Fenaux, Valeria Santini, Alan List

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

NLRP3炎症小体在骨髓增生异常综合征表型中发挥驱动作用

Basiorka, Ashley A; McGraw, Kathy L; Eksioglu, Erika A; Chen, Xianghong; Johnson, Joseph; Zhang, Ling; Zhang, Qing; Irvine, Brittany A; Cluzeau, Thomas; Sallman, David A; Padron, Eric; Komrokji, Rami; Sokol, Lubomir; Coll, Rebecca C; Robertson, Avril A B; Cooper, Matthew A; Cleveland, John L; O'Neill, Luke A; Wei, Sheng; List, Alan F

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

TP53 R72P 多态性与骨髓增生异常综合征疾病结局及 TP53 突变的关系

McGraw, K L; Zhang, L M; Rollison, D E; Basiorka, A A; Fulp, W; Rawal, B; Jerez, A; Billingsley, D L; Lin, H-Y; Kurtin, S E; Yoder, S; Zhang, Y; Guinta, K; Mallo, M; Solé, F; Calasanz, M J; Cervera, J; Such, E; González, T; Nevill, T J; Haferlach, T; Smith, A E; Kulasekararaj, A; Mufti, G; Karsan, A; Maciejewski, J P; Sokol, L; Epling-Burnette, P K; Wei, S; List, A F

Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors

来那度胺诱导脂质筏组装以增强骨髓增生异常综合征祖细胞中的促红细胞生成素受体信号传导

Kathy L McGraw, Ashley A Basiorka, Joseph O Johnson, Justine Clark, Gisela Caceres, Eric Padron, Ruth Heaton, Yukiyasu Ozawa, Sheng Wei, Lubomir Sokol, Alan F List

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients

TP53 抑制可促进 del(5q) MDS 中的红细胞生成,提示对来那度胺耐药患者可采取有针对性的治疗策略

Gisela Caceres, Kathy McGraw, Bon Ham Yip, Andrea Pellagatti, Joseph Johnson, Ling Zhang, Kenian Liu, Lan Min Zhang, William J Fulp, Ji-Hyun Lee, Najla H Al Ali, Ashley Basiorka, Larry J Smith, F Joseph Daugherty, Neil Littleton, Richard A Wells, Lubomir Sokol, Sheng Wei, Rami S Komrokji, Jacqueline